This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in Q4, an estimated trade size of $81.11 million using quarterly average pricing. The quarter-end Viridian position value declined by $49.79 million, reflecting the combination of the trade and underlying price movements.

Analysis

Kynam Capital sold 2,957,386 shares of Viridian Therapeutics in Q4, an estimated trade size of $81.11 million using quarterly average pricing. The quarter-end Viridian position value declined by $49.79 million, reflecting the combination of the trade and underlying price movements.